Complete Remission of Hormone Refractory Adenocarcinoma of the Prostate in Response to Withdrawal of Diethylstilbestrol
- 1 June 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 153 (6) , 1944-1945
- https://doi.org/10.1016/s0022-5347(01)67364-6
Abstract
The phenomenon of regression of adenocarcinoma of the prostate after the withdrawal of antiandrogens is well documented. However, to our knowledge we report the first case of durable complete remission of hormone refractory prostate cancer after cessation of diethylstilbestrol. The drug was discontinued because the patient had disease progression while on diethylstilbestrol and withdrawal resulted in durable remission. In more than 3 years of followup since discontinuing diethylstilbestrol there has been no evidence of clinical or biochemical recurrence.Keywords
This publication has 9 references indexed in Scilit:
- Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndromeUrology, 1994
- Heterogeneity of prostate cancer inradical prostatectomy specimensUrology, 1994
- Response to Flutamide Withdrawal in Advanced Prostate Cancer in Progression Under Combination TherapyJournal of Urology, 1993
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- Prostate Specific Antigen Decline after Antiandrogen Withdrawal: the Flutamide Withdrawal SyndromeJournal of Urology, 1993
- Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapyCancer, 1993
- Effect of Stilboestrol and Testosterone on the Incorporation of75Selenomethionine by Prostatic Carcinoma CellsBritish Journal of Urology, 1988
- The dedifferentiation of prostate carcinomaCancer, 1983
- THE PRESENT POSITION OF THE SURGERY OF THE HYPERTROPHIED PROSTATEAnnals of Surgery, 1893